We provide you with 20 years of free, institutional-grade data for DBVT stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DBVT. Explore the full financial landscape of DBVT stock.
| Reported Date | CIK | Ticker | Type |
|---|
DBV Technologies S.A(NASDAQ:DBVT) 
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergie...
Website: http://www.dbv-technologies.com
Founded: 2002
Full Time Employees: 311
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about DBVT stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.